Andrew Gengos

Andrew W.
Gengos is currently Director at Turn Therapeutics (TM), Inc., Independent Director at Turn Therapeutics, Inc. since 2020, Director at Seneca Therapeutics, Inc. starting 2025, and Chief Financial & Accounting Officer at Terns Pharmaceuticals, Inc. starting 2025.
Former positions include President, Chief Executive Officer & Director at ImmunoCellular Therapeutics Ltd. from 2012 to 2016; President, Chief Executive Officer & Director at Neuraltus Pharmaceuticals, Inc. from 2010 to 2012; Director at Allozyne, Inc.; Vice President-Strategy & Corporate Development at Amgen, Inc. from 2002 to 2010; Vice President-Strategy & Development at Chiron Corp.
in 2010; Chief Financial & Business Officer at Dynavax Technologies Corp.; Senior Manager-Engagement at McKinsey & Co., Inc. from 1991 to 1998; Vice President-Strategy & Corporate Development at Relypsa, Inc. in 2010; Chief Business Officer at Cyteir Therapeutics, Inc. from 2020 to 2023; COO & Head-Corporate Development at Synlogic, Inc. from 2017 to 2018; Chief Financial & Business Officer at AOBiome Therapeutics, Inc. in 2019; and Chief Financial & Business Officer at LeonaBio, Inc. from 2023 to 2024.
Education includes undergraduate studies at Massachusetts Institute of Technology and an MBA from UCLA Anderson School of Management.